F2R and Nephropathy: Before initiating clinical studies targeting PAR-1 in the setting of diabetic nephropathy it is therefore pivotal to establish whether pharmacological inhibition of PAR-1, started once diabetes has been established, also limits diabetes-induced kidney damage.